Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial
David M Loeb, Ji Won Lee, Daniel A Morgenstern, Yvan Samson, Anne Uyttebroeck, Chuhl Joo Lyu, An Van Damme, Karsten Nysom, Margaret E Macy, Alexandra P Zorzi, Julia Xiong, Petra Pollert, Ingrid Joerg, Yulia Vugmeyster, Mary Ruisi, Hyoung Jin Kang, David M Loeb, Ji Won Lee, Daniel A Morgenstern, Yvan Samson, Anne Uyttebroeck, Chuhl Joo Lyu, An Van Damme, Karsten Nysom, Margaret E Macy, Alexandra P Zorzi, Julia Xiong, Petra Pollert, Ingrid Joerg, Yulia Vugmeyster, Mary Ruisi, Hyoung Jin Kang
Abstract
Background: We report dose-escalation results from an open-label, phase 1/2 trial evaluating avelumab (anti-PD-L1) in paediatric patients with refractory/relapsed solid tumours.
Methods: In phase 1, patients aged < 18 years with solid (including central nervous system [CNS]) tumours for which standard therapy did not exist or had failed were enrolled in sequential cohorts of 3-6 patients. Patients received avelumab 10 or 20 mg/kg intravenously every 2 weeks. Primary endpoints were dose-limiting toxicities (DLTs) and grade ≥ 3 treatment-emergent adverse events (AEs).
Results: At data cut-off (27 July 2021), 21 patients aged 3-17 years had received avelumab 10 mg/kg (n = 6) or 20 mg/kg (n = 15). One patient had three events that were classified as a DLT (fatigue with hemiparesis and muscular weakness associated with pseudoprogression; 20 mg/kg cohort). Grade ≥ 3 AEs occurred in five (83%) and 11 (73%) patients in the 10 and 20 mg/kg cohorts, respectively, and were treatment-related in one patient (7%; grade 3 [DLT]) in the 20 mg/kg cohort. Avelumab exposure in paediatric patients receiving 20 mg/kg dosing, but not 10 mg/kg, was comparable or higher compared with approved adult dosing (10 mg/kg or 800 mg flat dose). No objective responses were observed. Four patients with CNS tumours (20 mg/kg cohort) achieved stable disease, which was ongoing in two patients with astrocytoma at cut-off (for 24.7 and 30.3 months).
Conclusion: In paediatric patients with refractory/relapsed solid tumours, avelumab monotherapy showed a safety profile consistent with previous adult studies, but clinical benefits were limited.
Trial registration: ClinicalTrials.gov NCT03451825.
Keywords: Avelumab; Immune checkpoint inhibitor; Immunotherapy; Paediatrics; Phase 1.
Conflict of interest statement
DAM reports serving as a consultant or advisor for Bayer, Boehringer Ingelheim, Clarity Pharmaceuticals, Roche, and Y-mAbs Therapeutics; is a member of a speakers bureau for EUSA Pharma; has received institutional research funding from Bristol Myers Squibb; and has received reimbursement for travel and accommodation expenses from EUSA Pharma and Y-mAbs Therapeutics. KN has received honoraria from and reports serving as a consultant or advisor for Bayer and Y-mAbs Therapeutics. MEM reports serving as a consultant or advisor for Ventana Medical Systems; has received institutional research funding from Bayer, Ignyta, Lilly, MSD, and Roche; holds stock in GE Healthcare, Johnson & Johnson, Teva Pharmaceuticals, and Varian Medical Systems; and has a patent for non-invasive methods of leukaemia cell detection with magnetic resonance imaging/magnetic resonance spectroscopy (US patent 8,894,975). JX was employed by EMD Serono Research & Development Institute Inc., Billerica, MA, USA, an affiliate of Merck KGaA at the time of manuscript preparation. PP and IJ report employment with Merck Healthcare KGaA, Darmstadt, Germany. YV reports employment with EMD Serono Research & Development Institute Inc., Billerica, MA, USA, an affiliate of Merck KGaA. MR reports employment with EMD Serono Research & Development Institute Inc., Billerica, MA, USA, an affiliate of Merck KGaA at the time of manuscript preparation, and holds stock in Bristol Myers Squibb. All other authors declare no competing interests.
© 2022. The Author(s).
Figures
References
- Cho HW, Lee JW, Ma Y, Yoo KH, Sung KW, Koo HH. Treatment outcomes in children and adolescents with relapsed or progressed solid tumors: a 20-year, single-center study. J Korean Med Sci. 2018;33(41):e260. doi: 10.3346/jkms.2018.33.e260.
- Majzner RG, Heitzeneder S, Mackall CL. Harnessing the immunotherapy revolution for the treatment of childhood cancers. Cancer Cell. 2017;31(4):476–485. doi: 10.1016/j.ccell.2017.03.002.
- Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial. Lancet Oncol. 2020;21(1):121–133. doi: 10.1016/S1470-2045(19)30671-0.
- Geoerger B, Zwaan CM, Marshall LV, Michon J, Bourdeaut F, Casanova M, Corradini N, Rossato G, Farid-Kapadia M, Shemesh CS, Hutchinson KE, Donaldson F, Liao M, Caron H, Trippett T. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study. Lancet Oncol. 2020;21(1):134–144. doi: 10.1016/S1470-2045(19)30693-X.
- Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ, Mackall CL. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol. 2020;21(4):541–550. doi: 10.1016/S1470-2045(20)30023-1.
- Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH, Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115. doi: 10.1056/NEJMoa1816047.
- Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbe C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374–1385. doi: 10.1016/S1470-2045(16)30364-3.
- Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S, Demey W, Ullen A, Loriot Y, Sridhar SS, Tsuchiya N, Kopyltsov E, Sternberg CN, Bellmunt J, Aragon-Ching JB, Petrylak DP, Laliberte R, Wang J, Huang B, Davis C, Fowst C, Costa N, Blake-Haskins JA, di Pietro A, Grivas P. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–1230. doi: 10.1056/NEJMoa2002788.
- Keilholz U, Mehnert JM, Bauer S, Bourgeois H, Patel MR, Gravenor D, Nemunaitis JJ, Taylor MH, Wyrwicz L, Lee KW, Kasturi V, Chin K, von Heydebreck A, Gulley JL. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. J Immunother Cancer. 2019;7(1):12. doi: 10.1186/s40425-018-0459-y.
- Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen FL, Delord JP, Dowlati A, Kochuparambil ST, Taylor MH, Powderly JD, Vaishampayan UN, Verschraegen C, Grote HJ, von Heydebreck A, Chin K, Gulley JL. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN Solid Tumor trial. JAMA Oncol. 2019;5(3):351–357. doi: 10.1001/jamaoncol.2018.5428.
- Bavencio (avelumab) Prescribing information. EMD Serono; (2020)
- Novakovic AM, Wilkins JJ, Dai H, Wade JR, Neuteboom B, Brar S, Bello CL, Girard P, Khandelwal A. Changing body weight-based dosing to a flat dose for avelumab in metastatic Merkel cell and advanced urothelial carcinoma. Clin Pharmacol Ther. 2020;107(3):588–596. doi: 10.1002/cpt.1645.
- Keytruda (pembrolizumab) Prescribing information. Whitehouse Station, Merck & Co., Inc, NJ (2022)
- Opdivo (nivolumab) Prescribing information. Princeton, NJ; Bristol-Myers Squibb (2021)
- Kelly K, Infante JR, Taylor MH, Patel MR, Wong DJ, Iannotti N, Mehnert JM, Loos AH, Koch H, Speit I, Gulley JL. Safety profile of avelumab in patients with advanced solid tumors: a pooled analysis of data from the phase 1 JAVELIN Solid Tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer. 2018;124(9):2010–2017. doi: 10.1002/cncr.31293.
- Ji Y, Wang SJ. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials. J Clin Oncol. 2013;31(14):1785–1791. doi: 10.1200/JCO.2012.45.7903.
- Wang Q, Gao J, Wu X. Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol. 2018;58:125–135. doi: 10.1016/j.intimp.2018.03.018.
- Vugmeyster Y, Grisic A-M, Brockhaus B, Rueckert P, Ruisi M, Dai H, Khandelwal A (in press) Avelumab dose selection for clinical studies in pediatric patients with solid tumors. Clin Pharmacokinet
- Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortes ML, Auclair D, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CWM, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz G. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218. doi: 10.1038/nature12213.
- Rauwolf KK, Rossig C. Redirecting T cells to treat solid pediatric cancers. Cancer Metastasis Rev. 2019;38(4):611–624. doi: 10.1007/s10555-019-09821-5.
- European Medicines Agency decision P/0361/2017 of 1 December 2017. . Accessed March 4 2021
- Pearson ADJ, Rossig C, Lesa G, Diede SJ, Weiner S, Anderson J, Gray J, Geoerger B, Minard-Colin V, Marshall LV, Smith M, Sondel P, Bajars M, Baldazzi C, Barry E, Blackman S, Blanc P, Capdeville R, Caron H, Cole PD, Jimenez JC, Demolis P, Donoghue M, Elgadi M, Gajewski T, Galluzzo S, Ilaria R, Jr, Jenkner A, Karres D, Kieran M, Ligas F, Lowy I, Meyers M, Oprea C, Peddareddigari VGR, Sterba J, Stockman PK, Suenaert P, Tabori U, van Tilburg C, Yancey T, Weigel B, Norga K, Reaman G, Vassal G. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. Eur J Cancer. 2020;127:52–66. doi: 10.1016/j.ejca.2019.12.029.
- Cacciotti C, Choi J, Alexandrescu S, Zimmerman MA, Cooney TM, Chordas C, Clymer J, Chi S, Yeo KK. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. J Neurooncol. 2020;149(1):113–122. doi: 10.1007/s11060-020-03578-6.
- Lwin Z, Gomez-Roca C, Saada-Bouzid E, Yanez E, Muñoz FL, Im SA, Castanon E, Senellart H, Graham D, Voss M, Doherty M, Lopez J, Ghori R, Kubiak P, Jin F, Norwood K, Chung HC. LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours. Ann Oncol. 2020 doi: 10.1016/j.annonc.2020.08.2271.
Source: PubMed